The primary objective is to determine if JAK1 specific inhibition is effective in treating
granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved
treatment. The primary outcome will be the percentage change in the body surface area (BSA)
involvement by GA after 6 months of treatment with abrocitinib 200 mg daily in 10 patients
with moderate to severe GA affecting at least 5% body surface area (BSA).